NervGen Pharma Corp.

Recent News

  • NervGen Pharma Provides a Development Update on Its Lead Product NVG-291

    Vancouver, British Columbia--(Newsfile Corp. - February 26, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today is providing an update to its development plan for its lead program, NVG-291. These...

    2020-02-26 7:00 PM ET
  • NervGen Pharma Appoints Bill Adams as Chief Financial Officer

    Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. William (Bill) Adams, CPA, CA, to the position of...

    2020-02-24 9:00 AM ET
  • NervGen Pharma Responds to Recent Increase in Market Activity

    Vancouver, British Columbia--(Newsfile Corp. - January 13, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, confirms that the Company's management is unaware of any undisclosed information or material change in...

    2020-01-13 11:53 AM ET
  • NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer

    Vancouver, British Columbia--(Newsfile Corp. - November 27, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. Paul Brennan to the position of President & CEO...

    2019-11-27 9:00 AM ET
  • NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio

    Vancouver, British Columbia--(Newsfile Corp. - November 21, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that, further to its press release dated November 18, 2019, it has...

    2019-11-21 9:30 AM ET
  • NervGen Pharma Receives Investment from Drug Manufacturing Partner

    Vancouver, British Columbia--(Newsfile Corp. - November 18, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares ...

    2019-11-18 9:30 AM ET
  • NervGen Pharma Expands Platform into Alzheimer's Disease

    Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating novel treatments for nerve damage and neurodegenerative diseases, today announced a research initiative to advance its proprietary therapeutic technology platform, currently in development...

    2019-10-28 8:30 AM ET
  • NervGen Pharma Announces Clinical Development Plan for the Treatment of Nerve Damage and Neurodegenerative Diseases

    Vancouver, British Columbia--(Newsfile Corp. - September 6, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the clinical development strategy for its compound, NVG-291, in two...

    2019-09-06 8:30 AM ET